Incannex (IXHL) Healthcare announces that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea, OSA, on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program’s momentum and execution.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IXHL:
- Incannex Healthcare Announces Psychedelic Therapies Joint Venture
- Incannex forms joint venture with Mind Medicine Australia
- Incannex Healthcare Transfers Listing to Nasdaq Capital Market
- Incannex Healthcare Cancels Series A Warrants
- Incannex cancels all outstanding Series A warrants following ATM execution